Andreas Hochhaus
Overview
Explore the profile of Andreas Hochhaus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
483
Citations
23198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Manz K, Heidel F, Koschmieder S, Schlag R, Lipke J, Stegelmann F, et al.
Leukemia
. 2025 Feb;
PMID: 40000843
Myeloproliferative neoplasms (MPN) are associated with a variety of symptoms that severely impact patients' quality of life and ability to perform daily activities. Recent studies showed differences in the perception...
2.
Morath O, Crodel C, Rinke J, Sander I, Tekbas A, Meggendorfer M, et al.
Hamostaseologie
. 2024 Dec;
PMID: 39708833
Background: The risk of thrombosis and bleeding in myelofibrosis (MF) has been historically underappreciated. We sought to investigate potential molecular and clinical risk factors for venous (VTE) and arterial (ATE)...
3.
Hochhaus A, Cortes J, Hughes T
N Engl J Med
. 2024 Dec;
391(23):2275-2276.
PMID: 39665664
No abstract available.
4.
Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch J, Eigendorff F, et al.
Ann Hematol
. 2024 Nov;
103(12):6061.
PMID: 39562361
No abstract available.
5.
Mathies V, Kipp A, Hammersen J, Schrenk K, Scholl S, Schnetzke U, et al.
Oncol Res Treat
. 2024 Nov;
48(1-2):26-36.
PMID: 39510054
Introduction: Cancer-related malnutrition is a highly prevalent, yet often overlooked concern in clinical practice. Although cancer-related management guidelines recommend standardized nutritional care, its implementation is scarce. The aim of this...
6.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
7.
Fleischmann M, Jentzsch M, Brioli A, Eisele F, Frietsch J, Eigendorff F, et al.
Ann Hematol
. 2024 Oct;
104(1):285-294.
PMID: 39453477
The combination of venetoclax with hypomethylating agents is currently the standard of care for elderly patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy. Despite its favorable efficacy, clinical...
8.
Wickel J, Schnetzke U, Sayer-Klink A, Rinke J, Borie D, Dudziak D, et al.
Cell Rep Med
. 2024 Oct;
5(11):101794.
PMID: 39447569
Lambert-Eaton myasthenic syndrome (LEMS) is an autoantibody-mediated disease of the neuromuscular junction characterized by muscular weakness. Autoantibodies to presynaptic P/Q-type voltage-gated calcium channels (VGCCs) induce defective neuromuscular function. In severe...
9.
Rollig C, Steffen B, Schliemann C, Mikesch J, Alakel N, Herbst R, et al.
J Clin Oncol
. 2024 Sep;
43(1):65-74.
PMID: 39284116
Purpose: To determine the optimal daunorubicin dose and number of 7 + 3 induction cycles in newly diagnosed AML, this randomized controlled trial compared a once daily dose of 60...
10.
Jabbour E, Apperley J, Cortes J, Rea D, Deininger M, Abruzzese E, et al.
Leukemia
. 2024 Sep;
38(10):2291.
PMID: 39223297
No abstract available.